In recent years, there has been significant progress in the treatment of malignant lymphoma, new drugs and new treatment strategies continue to emerge, such as chimeric antigen receptor (CAR) T cells immunotherapy. The issue of malignant lymphoma has received a lot of attention. The recent progress of malignant lymphoma reported in the 57th American Society of Hematology annual meeting were briefly introduced in this article.

The 14th International Conference on Malignant Lymphoma (ICML) was held in Lugano, Switzerland from June 14, 2017 to June 17, 2017. More than 3500 lymphoma experts and scholars attended this unprecedented conference. In particular, the Joint Forum on Union for China Lymphoma Investigators (UCLI)-ICML jointly organised by UCLI and ICML had greatly improved Chinese academic status in the field of lymphoma worldwide. Chinese experience on the treatment of T-cell lymphoma was exchanged during the conference. This paper reviews the recent progress in treatment of T-cell lymphoma in the meeting.

In recent years, immunotherapy has become an indispensable part in treatment of cancer, and the immune checkpoint inhibitors are the focus of attention. In the 58th American Society of Hematology (ASH) Annual Meeting, the application of immune checkpoint inhibitors in hematologic malignancies had been widely concerned. The recent progress of immune checkpoint inhibitors in hematologic malignancies in this annual meeting will be briefly introduced.

The treatments of multiple myeloma (MM) have been made remarkable progress in recent years,and especially in 2015,FDA approved a number of new drugs for treatment of relapsed and refractory MM.At the 21th European Hematology Association Annual Meeting,the issue of MM has received a lot of attention.The recent progress of MM in this conference will be briefly introduced in this review.

The 13th International Conference on Malignant Lymphoma (ICMC) was held in Lugano, Switzerland from June 17 to 20, 2015.There was the enormous progress in the treatment of chronic lymphocytic leukemia in the past years, especially in 2014, 4 new agents for the treatment of chronic lymphocytic leukemia were approved in USA and Europe, which caused great attention on the issue of chronic lymphocytic leukemia.The latest progress of chronic lymphocytic leukemia reported at the conference was briefly introduced in this paper.

0.05). Significant increment of aggregation piles right after flights was shown in both groups (p0.05).

Objective To investigate the applied value of diffusion tensor tractography(DTT) and visual evoked potential(VEP) for monitoring lumpectomy of lesion adjacent to the optic radiation.Methods Six patients with intracranial lesions adjacent to the optic radiation performed MRI DTT before operation in order to know relationship between the optic radiation and lesion.Neuronavigation was performed and VEP was recorded continuously during the operation.Results Pathological results of specimens showed that 2 cases were astrocytoma(WHOⅡ),1 case was oligodendroglioma(WHOⅡ),1 case was oligodendro-astrocytoma(WHOⅡ),1 case was anaplastic astrocytoma(WHOⅢ～Ⅳ),1 case was cavernous angioma.No patients were found visual deficit and VEP of 6 cases were normal postoperatively.Conclusions Combination neuronavigation with optic radiation DTT preoperatively and neuronavigation with real-time VEP intraoperatively are reliable to monitor the visual function and is helpful to perform neurosurgical planning near the visual pathway to avoid vision postoperative dysfunction.

Objective To discuss the cause and preventive measure of positive stump in gastric cancer.Method The clinical data of 426 patients with residual cancer after resection of gastric cancer were retrospectively analyzed.Result In these cases 37(8.7%,37/426) were found to have residual cancers at the margin of resection.Conclusion The incidence of residual cancer at the cut edge is closely related to gross type,size of cancer,tumor stage and degree of differentiation.

Objective To evaluate the rules and features of the pseudoenhancement phenomenon of renal cysts during the multi-phases of contrast enhanced MSCT scan.Methods Ninety one patients with 112 simple renal cysts with B-ultrasound,CT examination,improved clinically enrolled in this retrospective study.The attenuation of the renal cysts were measured blindly in the images of CT plain scan and scans of arterial,venal and secrete phases,and the attenuation change of the cysts between pre-and post-enhanced scans were calculated; the accuracies of pseudoenhancement judging were calculated with 10 HU,15 HU and 18 HU as a threshold;the size were recorded; degree of intra renal parenchyma of the cyst were also confirmed,and so renal cysts were divided into three groups:type Ⅰ,Ⅱ and Ⅲ; The differences of attenuation among 3 enhancement phases,different size,different type were analyzed statistically with the Kruskal-wallis rank sum test,the correlation between the diameter and the pseudoenhancement in each enhancement phases were analyzed statistically with Spearman test.Results The attenuation median of the 112 cysts in plain scan,arterial,venal and secrete phase was 6.0 HU,11.0 HU,12.0 HU and 12.0 HU respectively,there was significant difference(x2=53.32,P＜0.01).The attenuation of the cysts in enhanced phases was higher than unenhanced.The range of attenuation change of the cysts between pre-and postenhanced scans was-10 to 31 HU,the number of cysts in groups of pseudoenhancement of 1 to 5 HU and 6 to 10 HU in each enhanced phase was dominant.The pseudoenhancement median of arterial,venal and secrete phase was 4.0 HU,5.0 HU and 6.0 HU respectively,There was significant difference among three groups(x2=10.062,P＜0.01).Taking 10 HU,15 HU and 18 HU as threshold for judging pseudoenhancement,the accuracy was 83.0％(239/288),95.1％(274/288) and 96.9％(279/288) respectively; Pseudoenhancement of small cysts(≤10 mm) was higher than other groups in each enhancement phase,and there was significant difference(P＜0.05).Type Ⅰ,Ⅱ and Ⅲ renal cysts were 62,23 and 27 respectively,the pseudoenhancement median of type Ⅰ renal cyst was 5.0 HU,6.0 HU and 8.0 HU respectively in arterial,venous,and excretion phase,which were higher than Type Ⅱ and Ⅲ (P＜0.05).It showed low negative correlation between pseudoenhancemen and diameter in arterial,venous and secrete phase(r =-0.326,-0.332 and-0.447,P＜ 0.01).Conclusion The pseudoenhancement correlated with the renal cyst size,the type and the enhance phases,which should be considered when making diagnosis.

Objective To explore the significance of mediastinum drainage tube in prevention and treatment of intrathoracic anastomotic leak after esophagectomy. Methods The morbidity and prognosis of intrathoracic anas-tomotic leak after esophagectomy in 180 patients with esophageal or cardia carcinoma (group A) who used mediasti-num drainage tube in operation from 2006 to 2008 was studied retrospectively,and were compare with 154 patients (group B) without mediastinum drainage tube from 2004 to 2006. Results The morbidity of intrathoracic anasto-motic leak after esophagectomy was 1.67% (3/180) in group A,and 4.55% (7/154) in group B,but no difference between them(χ2=1.4807, P>0.05) were found. Compared to group B, the final diagnosis of anastomotic leak in group A was early [(6.7±0.6) vs (10.0±2.1) days after operation (t=2.62, P<0.05)] and the duration of fe-ver was short [(5.3±1.5)vs (43.0±20.9) hours (t=4.39, P<0.01)]. The prognosis of 3 cases in group A was well, who all recovered without operation and had shorten hospital days than group B [(23.7±5.9)d vs (45.3± 5.0)d,t=4.86,P<0.01)]. In 7 cases of group B,there were 5 cases underwent second operation,but only 3 cases recovered, the case fatality rate was 2.60% (4/154), higher than in group A (0, Fisher, P<0.05). Conclusions Although the mediastinum drainage tube used or not used in esophagectomy is unrelated with the occurrence of anas-tomotic leak, and the significance to use it is that it can help to discover anastomotic leak early, and control mediasti-num infection effectively without reoperation,and improve patients' prognosis.